Can you give examples of combined inhalers that contain a long‑acting muscarinic antagonist (LAMA) and a long‑acting β2‑agonist (LABA) with their respective doses?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Inhaladores Combinados LAMA-LABA Disponibles

Los inhaladores combinados LAMA-LABA disponibles incluyen varias opciones con dosis específicas que han demostrado superioridad sobre monoterapias en función pulmonar y reducción de exacerbaciones 1.

Combinaciones Fijas Disponibles

Las siguientes son las combinaciones LAMA-LABA en un solo inhalador con sus dosis respectivas:

Indacaterol/Glicopirronio (IND/GLY)

  • Dosis: Indacaterol 110 mcg / Glicopirronio 50 mcg
  • Frecuencia: Una vez al día
  • Este fue uno de los primeros LAMA-LABA combinados disponibles 2, 3

Umeclidinio/Vilanterol (UMEC/VI)

  • Dosis: Umeclidinio 62.5 mcg / Vilanterol 25 mcg
  • Frecuencia: Una vez al día
  • Ha demostrado reducción del 20% en exacerbaciones comparado con salmeterol/fluticasona 4, 3

Tiotropio/Olodaterol

  • Dosis: Tiotropio 5 mcg / Olodaterol 5 mcg
  • Frecuencia: Una vez al día
  • Disponible en inhalador de niebla suave (soft mist inhaler) 2, 5

Aclidinio/Formoterol

  • Dosis: Aclidinio 400 mcg / Formoterol 12 mcg
  • Frecuencia: Dos veces al día
  • Única combinación con dosificación dos veces al día 2, 5

Evidencia de Eficacia

Las combinaciones LAMA-LABA mejoran significativamente la función pulmonar (FEV1), reducen síntomas, mejoran el estado de salud y disminuyen exacerbaciones comparadas con monoterapias 1. Los estudios demuestran:

  • Mejora en FEV1 de aproximadamente 80-90% del efecto aditivo de los componentes individuales 3
  • Reducción de exacerbaciones superior a monoterapia LAMA o LABA 1
  • Reducción de exacerbaciones mayor que la combinación ICS/LABA 1
  • Menor riesgo de neumonía comparado con terapias que contienen corticosteroides inhalados 4

Consideraciones Prácticas

No existe evidencia de superioridad entre los diferentes dispositivos inhaladores (DPI con cápsula/tira, DPI con reservorio, o inhalador de niebla suave) en términos de efectividad o seguridad 6. La elección del dispositivo debe basarse en:

  • Capacidad del paciente para usar correctamente el dispositivo específico
  • Preferencia del paciente
  • Disponibilidad local

Advertencia Importante

Las guías GOLD 2024 recomiendan iniciar con LAMA-LABA en pacientes del grupo B (síntomas moderados-severos con 0-1 exacerbación) y grupo E (≥2 exacerbaciones o ≥1 hospitalización con eosinófilos <300 células/µL) 7. La terapia dual LAMA-LABA debe considerarse el tratamiento de elección en pacientes sin tratamiento de mantenimiento previo con EPOC sintomático 7.

References

2
Research

Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review.

International journal of chronic obstructive pulmonary disease, 2017

5
Research

An update on LAMA/LABA combinations for COPD.

Drug and therapeutics bulletin, 2017

Related Questions

What are common long-acting beta agonist (LABA) - long-acting muscarinic antagonist (LAMA) inhaler combinations in the United States?
What is the role of Advair (fluticasone-salmeterol) in Chronic Obstructive Pulmonary Disease (COPD) management?
What are alternative drug choices for a patient with Chronic Obstructive Pulmonary Disease (COPD) experiencing weakness on Trelegy (fluticasone furoate/umeclidinium/vilanterol)?
Can a long‑acting muscarinic antagonist (e.g., tiotropium) be used as the sole maintenance therapy in a patient with stable mild‑to‑moderate chronic obstructive pulmonary disease and few symptoms?
What is the next step for a patient experiencing shortness of breath (SOB), phlegm, and wheezing despite being on Albuterol Sulfate (Albuterol) HFA inhalation 108 mcg/actuation and Alvesco (Ciclesonide) 160 mcg/actuation, both administered as aerosol solutions twice daily (BID)?
How should a febrile infant be evaluated and managed?
How should a 42-year-old woman with mild, gradually onset low back pain, no neurological or sphincter deficits, and pain that improves with NSAIDs and posture modifications be managed?
How should a pemphigus patient receiving azathioprine be evaluated and managed for fever?
How should the respiratory rate be adjusted in an adult patient with carbon dioxide retention, respiratory acidosis, and dynamic hyperinflation?
What is the appropriate conservative management for a 60-year-old woman with a six‑month history of gradual mid‑lumbar back pain that worsens with prolonged standing, without radiation, neurologic deficits, or systemic signs?
What are the evidence‑based guidelines for assessing and managing acute diarrhea in adults and children?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question